TY - JOUR
T1 - Monoclonal gammopathies of undetermined significance
AU - Kyle, Robert A.
AU - Rajkumar, S. Vincent
N1 - Funding Information:
This was supported in part by a research grant, CA 62242, from the National Cancer Institute.
PY - 2005/12
Y1 - 2005/12
N2 - The monoclonal gammopathies include multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), primary systemic amyloidosis (AL), and Waldenström's macroglobulinemia (WM). At Mayo Clinic, almost 60% of patients with a monoclonal gammopathy have MGUS. MGUS is characterized by the presence of a serum monoclonal protein value <3 g/dL, fewer than 10% plasma cells in the bone marrow, no or a small amount of monoclonal protein in the urine, and absence of lytic bone lesions, anemia, hypercalcemia, or renal insufficiency related to the plasma-cell proliferative process. During long-term follow-up of 241 patients with MGUS seen at Mayo Clinic from 1956 to 1970, MM, WM, AL, or a related disorder developed in 64. To confirm the findings, we conducted a population-based study on MGUS in the 11 counties of southeastern Minnesota from 1960 to 1994. The risk of progression to a malignant plasma-cell disorder was 1% per year.
AB - The monoclonal gammopathies include multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), primary systemic amyloidosis (AL), and Waldenström's macroglobulinemia (WM). At Mayo Clinic, almost 60% of patients with a monoclonal gammopathy have MGUS. MGUS is characterized by the presence of a serum monoclonal protein value <3 g/dL, fewer than 10% plasma cells in the bone marrow, no or a small amount of monoclonal protein in the urine, and absence of lytic bone lesions, anemia, hypercalcemia, or renal insufficiency related to the plasma-cell proliferative process. During long-term follow-up of 241 patients with MGUS seen at Mayo Clinic from 1956 to 1970, MM, WM, AL, or a related disorder developed in 64. To confirm the findings, we conducted a population-based study on MGUS in the 11 counties of southeastern Minnesota from 1960 to 1994. The risk of progression to a malignant plasma-cell disorder was 1% per year.
KW - Monoclonal gammopathy
KW - Monoclonal gammopathy of undetermined significance (MGUS)
UR - http://www.scopus.com/inward/record.url?scp=22144434741&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22144434741&partnerID=8YFLogxK
U2 - 10.1016/j.beha.2005.01.025
DO - 10.1016/j.beha.2005.01.025
M3 - Review article
C2 - 16026745
AN - SCOPUS:22144434741
SN - 1521-6926
VL - 18
SP - 689
EP - 707
JO - Best Practice and Research: Clinical Haematology
JF - Best Practice and Research: Clinical Haematology
IS - 4 SPEC. ISS.
ER -